McCormick Q3 earnings per share drop 57% to $0.36; net sales jump 17% to USD 2.02 billion
Bitget2026/10/01 10:31- McCormick posted third-quarter net sales of $2.02 billion, up 17% from a year earlier.
- Operating income fell 25% to $217 million, while gross profit margin widened 1.9 percentage points to 39.3%.
- Net income attributable to McCormick dropped 57% to $97.6 million, and diluted EPS slid 57% to $0.36.
- Management said special charges, including transaction and integration costs and a non-cash impairment, reduced diluted EPS by $0.50.
- McCormick reaffirmed its FY26 outlook for net sales growth, adjusted operating income and adjusted EPS, and kept integration planning for the Unilever Foods deal on track.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks
Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.
Crypto prices
More
